Vital Healthcare Property Trust (NZX:VHP) delivered a robust FY26, marked by a successful management internalisation, 23.5% AFFO growth, and a stable distribution payout, underpinning its position as a leading healthcare infrastructure owner in Australasia.
- 23.5% increase in AFFO to $86.9 million
- 9.0% rise in net property income to $162.2 million
- Portfolio occupancy remains high at 97.2%
- Completed $229.1 million in developments including RDX and Endoscopy Auckland
- Refinanced $1.4 billion of debt with no maturities before April 2028
Internalisation Strengthens Vital’s Operating Model
FY26 was a watershed year for Vital Healthcare Property Trust (NZX:VHP), as it transitioned to an internally managed structure on 1 January 2026. This strategic move eliminated third-party management fees and aligned the Board, management, and Unit Holders more directly, sharpening governance and operational focus. The internalisation was backed by a $235 million capital raising, comprising a $190 million placement and a $45 million unit purchase plan, underscoring investor confidence.
Post-internalisation, Vital's Management Expense Ratio dropped to an annualised 0.53%, reflecting cost efficiencies. The Board also bolstered its expertise with the forthcoming appointment of Mark Menhinnitt, a seasoned executive with deep trans-Tasman property and investment experience, signaling Vital’s intent to execute its development pipeline with precision.
Robust Financial Performance Underpinned by Portfolio Quality
Vital reported a 23.5% surge in Adjusted Funds From Operations (AFFO) to $86.9 million, translating to 11.50 cents per unit (cpu), up 10.5% on the prior year. This growth was fueled by a 9.0% increase in net property income (NPI) to $162.2 million, with like-for-like constant currency growth of 4.1%. The trust maintained distributions at 9.75 cpu, yielding an AFFO payout ratio of 84.8%, balancing income stability with growth.
Portfolio occupancy held firm at 97.2%, supported by over 27,600 square metres of leasing activity. Notably, the recently completed RDX development in Queensland is progressing towards stabilised occupancy, with approximately 70% of net lettable area under binding leases or agreements. Although underlying occupancy is currently 13%, an income guarantee from Northwest underwrites about 52% of net income until February 2027, providing a cushion during the ramp-up phase.
Development Pipeline Advances with Sustainability Credentials
Vital completed three key developments during FY26; Boulcott Hospital expansion, Endoscopy Auckland, and RDX; totaling $229.1 million in investment. Both RDX and Endoscopy Auckland achieved prestigious Green Star certifications, with RDX attaining a 6 Star rating (Australia) and Endoscopy Auckland securing New Zealand’s first 5 Star Green Star private hospital certification. These accolades highlight Vital’s commitment to sustainable, energy-efficient healthcare infrastructure.
Looking ahead, Vital has seven committed developments valued at $247.4 million, with $187.7 million remaining to be spent. Projects like Coomera Health Campus Stage 1 and Macarthur Health Precinct Stage 2 are progressing, targeting 5 Star Green Star ratings and pre-leased to leading healthcare operators such as Ramsay Health Care, Sonic Healthcare, and Lumus Imaging. These developments are expected to underpin long-term earnings growth and enhance portfolio quality.
Disciplined Capital Management Enhances Financial Flexibility
Vital refinanced approximately $1.4 billion of debt during FY26 on improved terms, extending the weighted average debt maturity to 4.3 years with no maturities before April 2028. The trust’s gearing ratio decreased to 39.6% from 42.1%, reflecting a prudent approach to leverage amid rising interest rates. Interest costs are substantially hedged, with 80% of borrowings fixed at an average rate of 3.45%, mitigating exposure to rate volatility.
Asset recycling remained a strategic priority, with $97.9 million realised from divestments at an average discount of ~4% to book value. These proceeds are being reinvested into higher-return development opportunities, reinforcing Vital’s capital recycling discipline.
Sector Fundamentals and Portfolio Positioning Support Long-Term Growth
Vital’s portfolio, valued at approximately $3.5 billion, spans 34 income-producing healthcare properties across New Zealand and Australia, including ~2,000 licensed beds. The trust’s tenant base comprises leading healthcare operators such as Aurora Healthcare, Healthe Care, Evolution Healthcare, and Epworth HealthCare, with a weighted average lease expiry (WALE) of 18.1 years, providing long-term income visibility.
Structural tailwinds underpin demand for Vital’s assets: population growth, ageing demographics, and constrained public healthcare systems in both countries drive sustained need for private healthcare infrastructure. Vital’s focus on essential healthcare real estate, combined with its trans-Tasman expertise, positions it uniquely to capitalise on these trends.
Governance Enhancements and Executive Remuneration Alignment
The internalisation enhanced Vital’s governance framework, with the Board assuming direct oversight of strategy, capital allocation, and executive remuneration. The newly established People and Culture Committee oversees remuneration policies designed to attract and retain specialist healthcare property talent across New Zealand and Australia.
CEO Chris Adams’ remuneration includes fixed salary, short-term incentives linked to strategic and financial objectives, and a Long-Term Incentive Plan (LTIP) aligned with total shareholder return and service conditions, reinforcing alignment with Unit Holder interests.
What to Watch Next
While the FY26 results reflect strong execution and portfolio resilience, the leasing progress at RDX remains a key focus. The trust anticipates stabilised occupancy to take approximately 18 months post-completion, with leasing outcomes there likely to influence near-term earnings growth. Additionally, the Board’s guidance for FY27 distributions at 9.75 cpu will be monitored closely as development leasing progresses. The unfolding impact of internalisation on operational agility and cost structure will also be pivotal as Vital navigates a rising interest rate environment and pursues disciplined capital allocation.
Bottom Line?
Vital’s internalisation has laid a strong foundation, but the pace of leasing at key developments and disciplined capital deployment will be critical to sustaining growth and distribution stability.
Questions in the middle?
- How will leasing conversion at RDX progress over the next 18 months and impact earnings?
- What are the risks and opportunities in Vital’s $247 million committed development pipeline?
- How might rising interest rates and refinancing cycles affect Vital’s cost of capital and valuation?